• Transactions
  • Careers
  • Contact
  • Client Login
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer

Leerink Partners

Helping our clients move healthcare forward

  • Sectors
    • Biopharma
    • Digital Health & HealthTech
    • Healthcare Services
    • Medical Technology
    • Tools & Diagnostics
  • Solutions
    • For Corporates
      • M&A Advisory
      • Capital Markets
      • Leveraged and Private Capital Markets
    • For Investors
      • Equity Research
      • Institutional Equities
      • Corporate Access
  • Intelligence
    • Perspectives
    • MEDACorp
  • Firm
    • About
    • Careers
    • News
    • Transactions

Redefining Investment Banking

An investment bank uniquely dedicated to serving innovation-driven and growth-minded healthcare and life science companies.

View Recent Transaction

Why Partner With Us

At Leerink Partners, we share a singular goal to achieve the highest level of success for our clients. We pride ourselves on being the most focused and passionate investment banking professionals in the business.

Learn more

1,155+

Transactions Completed

since 2009Learn More

$150+

Billion
Raised

since 2009Learn More

~260+

Companies
Covered

as of 8/31/2023Learn More

20K+

Key Opinion Leaders in Healthcare

as of 12/31/2020Learn More

Our Expertise

We provide healthcare companies and investors with a broad suite of financial solutions including M&A advisory, equity and debt capital markets, proprietary research, and comprehensive sales and trading capabilities.

Capital Markets

We are a market leader partnering with innovative healthcare companies throughout their financial lifecycle. Learn More

M&A Advisory

We leverage our long-term relationships, highly-regarded sector knowledge and transaction experience to deliver outcomes for our clients. Learn More

Institutional Equities

Delivering unique insights on equity-related products for institutional clients. Learn More

Equity Research

Industry-recognized equity research analysts offer a differentiated and unique perspective on the healthcare sectors driving innovation. Learn More

Leveraged and Private Capital Markets

Corporate clients and financial sponsors require expertise in structuring, underwriting, and syndicating a broad array of debt financing solutions. Learn more

MEDACorp

Exclusive access to Key Opinion Leaders (KOLs) and healthcare professionals is an essential service for our Equity Research and Investment Banking teams and healthcare clients as they evaluate opportunities. Learn More

Recent Transactions

See all transactions

$300 Million

Joint Placement Agent
PIPE
September 2023

$450 Million

Joint Bookrunner
Common Stock Financing
September 2023

UNDISCLOSED

Lead Financial Advisor
Sale to Azurity Pharmaceuticals, a Portfolio Company of QHP Capital
September 2023

$100 Million

Joint Bookrunner
Follow-On
September 2023

$350 Million

Joint Bookrunner
Follow-On
September 2023

$175 Million

Joint Bookrunner
Follow-On
September 2023

$70 Million

Joint Bookrunner
Follow-On
August 2023

Up to $213 Million

Financial Advisor
Sale to Regeneron
Pending

Up to $291 Million

Financial Advisor
Acquisition of Spectrum Pharmaceuticals
July 2023

$80 Million

Joint Bookrunner
Initial Public Offering
July 2023

$212 Million

Lead Placement Agent
Private Placement
July 2023

UNDISCLOSED

Exclusive Financial Advisor
Merger with Neurogene
Pending

Recent News

View All
Leerink Partners Successfully Completes Management Buy-Out
Learn More
Leerink Partners Serves as Joint Placement Agent for Structure Therapeutics’ (Nasdaq: GPCR) $300 Million Private Investment in Public Equity (PIPE)
Learn More
Leerink Partners Serves as Lead-Left Bookrunner for Immunovant’s (Nasdaq: IMVT) $450 Million Common Stock Financing
Learn More
Leerink Partners Serves as Joint Bookrunner for HilleVax’s (Nasdaq: HLVX) $100 Million Follow-On Offering
Learn More
Leerink Partners Serves as Joint Bookrunner for Rocket Pharmaceuticals’ (Nasdaq: RCKT) $175 Million Follow-On Offering
Learn More
Leerink Partners Serves as Joint Bookrunner for Crinetics Pharmaceuticals’ (Nasdaq: CRNX) $350 Million Upsized Follow-On Offering
Learn More
Leerink Partners Serves as Joint Bookrunner for AN2 Therapeutics’ (Nasdaq: ANTX) $70 Million Follow-On Offering
Learn More
Leerink Partners Bolsters Equity Research Team with Hire of Michael Cherny
Learn More

Featured Intelligence

View additional intelligence
Articles

Navigating the Complex Terrain: Healthcare and Biotech Markets in Q3 2023

September 2023
Podcasts

Sift Founder & CEO Justin Nicols – Episode 7

September 2023
Featured Research

Biopharma / Bullish on the CAH Opportunity

September 2023

Partner with Us

to achieve your strategic, capital markets, and investment objectives.

Contact Us

Footer

Sectors

  • Biopharma
  • Digital Health & HealthTech
  • Healthcare Services
  • Medical Technology
  • Tools & Diagnostics

Solutions

  • For Corporates
  • For Investors
  • Transactions
  • Advisory

Intelligence

  • Perspectives
  • Research
  • MEDACorp

Firm

  • About
  • Careers
  • News

Contact

  • General
  • Investors
  • Press

Stay ahead of what’s next. Sign Up Now!

Subscribe to receive our thought leadership and marketing updates.

This field is for validation purposes and should be left unchanged.

Member  FINRA/SIPC

  • Terms of Use
  • Privacy
  • Cookies
  • Notice to California Residents
  • Important Disclosures
  • Linkedin
  • Mail

Contact Us

Thank you for visiting Leerink.com. If you would like more information, please submit an inquiry below.

"*" indicates required fields

Name*